MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Cash and Cash Equivalents 2011-2025 | RMTI
Annual Cash and Cash Equivalents Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.98 M | 10.1 M | 13.3 M | 48.7 M | 11.8 M | 22.7 M | 8.41 M | 17.2 M | 31.2 M | 65.8 M | 11.9 M | 4.71 M | 5.72 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 65.8 M | 4.71 M | 20 M |
Quarterly Cash and Cash Equivalents Rockwell Medical
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.6 M | 12.5 M | 15.7 M | 12.3 M | 11.9 M | 6.64 M | 8.98 M | 7.76 M | 8.96 M | 10.9 M | 10.1 M | 13 M | 30.8 M | 9.91 M | 13.3 M | 23.4 M | 32.4 M | 35.7 M | 48.7 M | 48.7 M | 48.7 M | 48.7 M | 11.8 M | 11.8 M | 11.8 M | 11.8 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 8.41 M | 8.41 M | 8.41 M | 8.41 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 31.2 M | 31.2 M | 31.2 M | 31.2 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 4.71 M | 4.71 M | 4.71 M | 4.71 M | 5.72 M | 5.72 M | 5.72 M | 5.72 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65.8 M | 4.71 M | 20.5 M |
Cash and Cash Equivalents of other stocks in the Drug manufacturers industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
12.1 M | - | - | $ 142 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
37.2 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
114 M | $ 1.16 | - | $ 125 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
8.86 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
1.08 M | - | 0.86 % | $ 117 M | USA |
 |
Catalent
CTLT
|
289 M | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
2.56 M | - | 10.11 % | $ 58.2 M | USA |
 |
DURECT Corporation
DRRX
|
28.4 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
55.3 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
138 M | $ 4.26 | - | $ 86.3 M | Canada |
 |
Endo International plc
ENDP
|
778 M | - | - | $ 28.9 M |  Irlanda |
 |
Zomedica Corp.
ZOM
|
13 M | - | -0.21 % | $ 98 M | USA |
 |
Evoke Pharma
EVOK
|
4.74 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
956 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
83.2 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
50.6 M | - | - | $ 55.5 M | USA |
 |
Emergent BioSolutions
EBS
|
112 M | $ 12.16 | - | $ 623 M | USA |
 |
Athenex
ATNX
|
30.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
51.4 M | $ 21.54 | - | $ 2.05 B |  France |
 |
Evolus
EOLS
|
87 M | $ 6.67 | 0.15 % | $ 414 M | USA |
 |
Harrow Health
HROW
|
74.1 M | $ 50.02 | -1.46 % | $ 1.63 B | USA |
 |
OrganiGram Holdings
OGI
|
24.6 M | $ 1.7 | - | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
600 K | $ 1.33 | - | $ 23.2 M |  China |
 |
Organogenesis Holdings
ORGO
|
136 M | $ 5.18 | - | $ 682 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
148 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
947 M | $ 6.99 | - | $ 2.55 B | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
5.37 M | $ 3.62 | - | $ 4.49 M | USA |
 |
Lannett Company
LCI
|
87.9 M | - | 1.15 % | $ 7.11 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
18 M | $ 3.96 | - | $ 55.7 M | USA |
 |
Pacira BioSciences
PCRX
|
277 M | $ 26.07 | - | $ 1.21 B | USA |
 |
Sundial Growers
SNDL
|
218 M | $ 1.65 | - | $ 3.37 M | Canada |
 |
Veru
VERU
|
24.9 M | $ 2.17 | - | $ 293 M | USA |
 |
PetIQ
PETQ
|
116 M | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
349 K | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
559 M | $ 13.94 | - | $ 1.92 B | USA |
 |
ProPhase Labs
PRPH
|
9.11 M | $ 0.45 | - | $ 7.13 M | USA |
 |
cbdMD
YCBD
|
2.45 M | $ 1.36 | - | $ 5.87 M | USA |
 |
Radius Health
RDUS
|
112 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
8.1 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.09 M | $ 4.53 | - | $ 136 M | USA |
 |
OptiNose
OPTN
|
73.7 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
73.4 M | $ 9.2 | - | $ 653 M | USA |
 |
PLx Pharma
PLXP
|
69.4 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
80.2 M | $ 5.7 | - | $ 233 M | USA |
 |
SCYNEXIS
SCYX
|
34 M | $ 0.61 | - | $ 29.2 M | USA |
 |
Tricida
TCDA
|
21.1 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
207 M | $ 9.02 | - | $ 5.57 B | Canada |
 |
TherapeuticsMD
TXMD
|
4.33 M | $ 1.64 | - | $ 17.1 M | USA |